|
 |
|
|
|
|
|
|
|
|
||||||
Migraine New Jersey |
||||||
MigraineNO DRUGS, NO SURGERY
The FDA has granted marketing allowance for the NTI Tension Suppression System (NTI-tss) indicated for the prevention and treatment of medically diagnosed migraine and migraine associated tension-type headache pain. In a multi-center clinical trial, the NTI-tss device was shown to significantly reduce or eliminate migraine and migraine associated pain. It is considered breakthrough technology in that there is, when used as directed, no risk of side effects associated with it compared to many current pharmaceutical migraine therapies. Typical migraine sufferers awake each morning with varying degrees of migraine pain and have come to accept it as normal. Patients who experience such migraine headaches contract their temporal muscles during sleep on average 14 times more intensely than patients who do not experience them, and have been found to exhibit pericranial tenderness (muscle tenderness of the scalp). The NTI-tss device is a small, removable, prefabricated, clear resin matrix oral insert that a dentist fits to the patient’s front teeth to be worn while sleeping. With the NTI-tss device in place, the intense activity of the temporal muscle (which closes and clenches the jaw) is suppressed to less than 1/3 of maximum by preventing any contacting of the back molar teeth. By reducing this neuromuscular activity, migraine headache pain is reduced or prevented all together, as well as the migraine associated tension-type headaches. In the United States, according to the results of the 1992 American Migraine Study that appeared in The Journal of the American Medical Association, it is estimated that 23 million persons older than 12 years of age suffer severe migraine headaches. The social and economic impact of migraine is staggering, with estimates approaching $17.2 billion per year in lost productivity. There is no known cause of or cure for chronic migraine. Commonly prescribed migraine drugs have not been shown to prevent or stop every incident of migraine, and their benefit does not exceed 50% greater than treatment with placebo. The pivotal NTI-tss clinical trial involved 94 patients. Each patient was diagnosed by a physician as having at least two migraine episodes per month. Each patient was prescribed Imitrex® (sumatriptan, GlaxoSmithKline) by a physician for use as a migraine rescue medication. The patients were divided into two groups. Fifty-one (51) patients were fitted with the control device, and 43 patients were fitted with the NTI-tss device. After eight weeks of NTI-tss use, patients in the NTI-tss group did not experience any measurable evidence of new pain or discomfort as a result of using the NTI-tss. The device did not cause pain in use. Clinical performance data showed a decrease of migraine episodes of 61.9% with the NTI-tss device compared to 38.1% with the control. (82% of the NTI-tss users had a 77% average reduction of migraine events.) The need for Imitrex® rescue for the NTI-tss group was reduced by 46.8% compared to 17.6% for the control group. The NTI-tss group showed a 78% reduction in nausea compared to a 40.4% reduction in the control group. NTI-tss reduced all head pain episodes by 46.9% compared to a 25.1% reduction by the control and a 36.9% reduction in the intensity of head pain versus a 23.7% reduction by the control. In our office, we can fabricate the removable NTI-tss device in one visit. The device is worn primarily while asleep. Many dentists across the country are already highly experienced in its use after years of providing the NTI-tss for its earlier indications for the prevention of TMJ syndrome, grinding, clenching, and bruxism. Approximately 200,000 patients have been treated to date for these indications.
| ||||||
| Migraine Treatment 455 River Road New Milford, NJ 07646 Bergen County, New Jersey 201-261-3342
migraine treatment new jersey migraine treatment new jersey migraine treatment new jersey |
||||||
